Unanswered questions on omalizumab (Xolair) patient selection and follow-up.
Lanier
Bobby
B
Marshall
Gailen D
GD
D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D000069444:Omalizumab
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab